By: Adelaide Taylor Introduction The global food industry is facing an unprecedented disruption. For decades, consumer packaged goods companies have designed products around a universal craving for sugary, salty, and fatty flavor profiles. However, the astronomical rise of glucagon-like peptide-1 (GLP-1) receptor agonists—weight-loss medications like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound)—is completely reshaping consumer habits. The Taste Bud Revolution: Why NestlĂ© and Big Food Are Rewriting Recipes for the GLP-1 Generation Recent reporting highlights an unexpected side effect altering the grocery store landscape: GLP-1 medications are structurally warping consumers' taste buds. Facing scaled-back appetites and altered palates among millions of consumers, the world's largest food company, NestlĂ©, is aggressively pivoting its portfolio. By adjusting portion sizes, expanding functional nutrient profiles, and developing bold, spicier profiles tailored to ...
Comments
Post a Comment
If you have any doubt, please let me know